NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Residual Replication of HIV-1 in the Gut Associated Lymphoid Tissue (GALT) of Patients on Highly Active Antiretroviral Therapy (HAART): the ANRS EP 44 Study

NCT01038401

CompletedNA

Sponsor: ANRS, Emerging Infectious Diseases

Conditions: HIV Infection

Interventions: GI endoscopy and GALT biopsies, A sample of venous blood will also be collected

Countries: France

HIV-1 cannot be eradicated from infected individuals by current antiretroviral regimens. Cellular reservoirs and tissue sanctuary sites allow latent HIV-1 persistence and ongoing low-level virus replication. This project aims to characterize the residual replication of HIV-1 in subjects on antiretroviral therapy, particularly in the gut-associated lymphoid tissue.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* HIV-1 infection (ELISA and western-blot tests)
* Continuous antiretroviral therapy \>= 12 months
* Plasma HIV-1 RNA =\< 40 copies/ml \>= 6 months
* Indication of gastro-intestinal endoscopy
* Age \>= 18-year old
* Physical examination
* Informed consent

Exclusion Criteria:

* Plasma HIV-1 RNA \> 40 copies/ml in the last 6 months
* Involvement in a HIV vaccine study
* Treatment with interferon-alpha or PEG- interferon-alpha in the last 6 months
* Treatment with interleukin-2 in the last 6 months
* Decompensated cirrhosis
* Abnormal hemostasis tests
* Inflammatory bowel disease ; coeliac disease
* Lymphoma
* Blood transfusion in the last 6 months
* Absence of social security (health insurance)
* Pregnant or breastfeeding woman
* Incapable adult

Locations (1)

Toulouse, France